-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
SMCypI-C31
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2649904-85-6.gif)
| Category | Hepatitis C Virus (HCV) |
| CAS | 2649904-85-6 |
| Description | SMCypI C31 is a non-peptidic cyclophilin inhibitor with potent peptidyl-prolyl cis/trans isomerases (PPIase) inhibitory activity (IC50 of 0.1 µM). SMCypI C31 shows pangenotype anti-HCV activity with EC50s ranging from 1.20 to 7.76 μM for genotype 1a, 1b, 2a, 3a, and 5a HCV subgenomic replicons (HCV-SGRs) and chimeric genotype 2a/4a HCV-SGRs. SMCypI C31 disrupts the cyclophilin A-NS5A interaction. |
Product Information
| Molecular Weight | 474.62 |
| Molecular Formula | C27H30N4O2S |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| In Vitro | SMCypI C31 (C31) inhibited the replication of genotype 1a, 1b, 2a, 3a, and 5a HCV-SGRs and chimeric genotype 2a/4a HCV-SGRs, with EC50 values of 3.80 µM, 2.95 µM, 2.30 µM, 7.76 µM, 1.20 µM and 1.40 µM, respectively. SMCypI C31 also inhibits the replication of the infectious J6/JFH1 virus, with an EC50 of 2.80 μM. SMCypI C31 inhibits DBN-3acc RNA replication in a dose-dependent manner, with a maximal 244-fold HCV RNA reduction at 10 μM. SMCypI C31 (C31) inhibits the replication of other members of the Flaviviridae family. SMCypI C31 inhibits viral replication of DENV (EC50 of 7.3 μM), YFV (EC50 of 27.2 μM), and ZIKV (EC50 of 48.0 μM). |
| PSA | 17.07000 |
| Target | IC50: 0.1 µM (Peptidyl-prolyl cis/trans isomerases (PPIase)) |
